Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | TP53 | P04637 | 7/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13266365 | 0.91 | RXFP1 (0.40) | POLBUSP2RXFP1CRHBPCRHR2 | |
| SCHEMBL2575623 | 0.88 | FADS1 (0.46) | FADS1POLBUSP2RXFP1CRHBP | |
| SCHEMBL2561992 | 0.84 | ALDH1A1 (0.43) | FADS1KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL2564170 | 0.83 | FADS1 (0.49) | FADS1POLBUSP2RXFP1CRHBP | |
| SCHEMBL2575626 | 0.82 | FADS1 (0.64) | FADS1POLBUSP2RXFP1CRHBP | |
| SCHEMBL2566730 | 0.81 | FADS1 (0.42) | FADS1POLBRXFP1ALDH1A1LMNA | |
| SCHEMBL2997555 | 0.80 | FADS1 (0.46) | FADS1RXFP1ALDH1A1MAPTTP53 | |
| SCHEMBL2561188 | 0.80 | FADS1 (0.42) | FADS1POLBRXFP1KDM4EALDH1A1 | |
| SCHEMBL2578908 | 0.80 | ALDH1A1 (0.42) | FADS1USP2KDM4EALDH1A1LMNA | |
| SCHEMBL2565032 | 0.80 | TSHR (0.45) | FADS1POLBKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190747-A1 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190747-A1 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190747-A1 | Fused ring compound and use thereof | CYP46A1, LTB4R2, PTGES | FADS1 140/4885POLB 4165/4885USP2 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.